NICE in final appraisal rejects Abraxane(nab-paclitaxel) for metastatic pancreatic cancer-Celgene
The National Institute for Health and Care Excellence (NICE) has in a final appraisal rejected Abraxane (nab-paclitaxel) from Celgene for treatment of previously treated pancreatic cancer on the grounds of cost effectiveness and its serious side effects, in fact, more side effects than the gemcitabine + capicitabine combination.
Comment:The decision met criticism from Pancreatic Cancer Action which noted that Abraxane was becoming the standard of care for metastatic pancreatic cancer patients in Europe and North America and the decision was unfair to patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.